EP4463166A4 - Irak4-abbauer und verwendungen davon - Google Patents

Irak4-abbauer und verwendungen davon

Info

Publication number
EP4463166A4
EP4463166A4 EP23740879.4A EP23740879A EP4463166A4 EP 4463166 A4 EP4463166 A4 EP 4463166A4 EP 23740879 A EP23740879 A EP 23740879A EP 4463166 A4 EP4463166 A4 EP 4463166A4
Authority
EP
European Patent Office
Prior art keywords
democraft
iraq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23740879.4A
Other languages
English (en)
French (fr)
Other versions
EP4463166A1 (de
Inventor
Reginald Ewesuedo
Chris Ho
William Leong
Jared Gollob
Jeffrey Davis
Ashwin Gollerkeri
Alice Mcdonald
Vashali Dixit
Shu-Pei Wu
Michele Mayo
Haojing Rong
Sagar Agarwal
Bradley Enerson
Patrick Henrick
Rachelle Perea
Duncan Walker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kymera Therapeutics Inc
Original Assignee
Kymera Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kymera Therapeutics Inc filed Critical Kymera Therapeutics Inc
Publication of EP4463166A1 publication Critical patent/EP4463166A1/de
Publication of EP4463166A4 publication Critical patent/EP4463166A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP23740879.4A 2022-01-14 2023-01-13 Irak4-abbauer und verwendungen davon Pending EP4463166A4 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263299653P 2022-01-14 2022-01-14
US202263267465P 2022-02-02 2022-02-02
US202263387274P 2022-12-13 2022-12-13
PCT/US2023/060645 WO2023137439A1 (en) 2022-01-14 2023-01-13 Irak4 degraders and uses thereof

Publications (2)

Publication Number Publication Date
EP4463166A1 EP4463166A1 (de) 2024-11-20
EP4463166A4 true EP4463166A4 (de) 2025-12-31

Family

ID=87279804

Family Applications (1)

Application Number Title Priority Date Filing Date
EP23740879.4A Pending EP4463166A4 (de) 2022-01-14 2023-01-13 Irak4-abbauer und verwendungen davon

Country Status (4)

Country Link
US (1) US20230277519A1 (de)
EP (1) EP4463166A4 (de)
TW (1) TW202345827A (de)
WO (1) WO2023137439A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
CA3119773A1 (en) 2018-11-30 2020-06-04 Kymera Therapeutics, Inc. Irak degraders and uses thereof
JP2023509366A (ja) 2019-12-17 2023-03-08 カイメラ セラピューティクス， インコーポレイテッド Ｉｒａｋ分解剤およびそれらの使用
TW202241891A (zh) 2020-12-30 2022-11-01 美商凱麥拉醫療公司 Irak降解劑及其用途
MX2023009178A (es) 2021-02-15 2023-08-21 Kymera Therapeutics Inc Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos.
WO2023147594A2 (en) 2022-01-31 2023-08-03 Kymera Therapeutics, Inc. Irak degraders and uses thereof
US20240252656A1 (en) * 2022-10-13 2024-08-01 Kymera Therapeutics, Inc. Salt forms of irak4 degraders
WO2024191788A1 (en) * 2023-03-10 2024-09-19 Kymera Therapeutics, Inc. Irak4 degraders and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021127190A1 (en) * 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Irak degraders and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102828518B1 (ko) * 2017-05-26 2025-07-04 캔써 리서치 테크놀로지 리미티드 벤즈이미다졸론 유래된 bcl6의 저해제
IL315310A (en) * 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
EP3817822A4 (de) * 2018-07-06 2022-07-27 Kymera Therapeutics, Inc. Proteinabbaumittel und verwendungen davon

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021127190A1 (en) * 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Irak degraders and uses thereof

Also Published As

Publication number Publication date
US20230277519A1 (en) 2023-09-07
TW202345827A (zh) 2023-12-01
WO2023137439A1 (en) 2023-07-20
EP4463166A1 (de) 2024-11-20

Similar Documents

Publication Publication Date Title
EP4463166A4 (de) Irak4-abbauer und verwendungen davon
EP4326720A4 (de) Parp1-inhibitoren und verwendungen davon
EP4095671A4 (de) Screencasting-verfahren und endgerät
EP4262883C0 (de) Peg-lipide und lipidnanopartikel
EP4159738A4 (de) Makrocyclischer jak-hemmer und verwendungen davon
EP4421074A4 (de) Parp-1-abbaumittel und verwendung davon
EP4393937A4 (de) Steroidverbindung und konjugat davon
EP4200301C0 (de) Phospholipidverbindungen und verwendungen davon
EP4466269A4 (de) Parp1-inhibitoren und verwendungen davon
EP4353249A4 (de) Multiagonist und verwendung davon
EP4126844A4 (de) Amidverbindungen und verwendungen davon
EP4450501A4 (de) Cdk9-inhibitor und verwendung davon
EP4499104A4 (de) Tyk2-inhibitoren und verwendungen davon
EP4244205A4 (de) Ire1alpha-inhibitoren und verwendungen davon
EP4161917A4 (de) Grk2-inhibitoren und verwendungen davon
EP4406537A4 (de) Langkettige verbindung und verwendung davon
EP4285937A4 (de) Konjugat und verwendung davon
EP4408853A4 (de) Lpxc-hemmer und verwendungen davon
IL313171A (en) Il10 variants and uses thereof
EP4305021A4 (de) Usp30-inhibitoren und verwendungen davon
EP4198040C0 (de) Pt-dpephos-iod-komplex und pt-dpephos-brom-komplex
EP4453000A4 (de) Auristatin-analoga und immunokonjugate davon
EP4578945A4 (de) Crispr-cas13-system und verwendung davon
EP4471005A4 (de) Konjugat und verwendung davon
EP4387613A4 (de) Konjugate von monocyclischen beta-lactamen und siderophormimetika

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240711

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20251203

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/5386 20060101AFI20251127BHEP

Ipc: A61K 31/44 20060101ALI20251127BHEP

Ipc: A61K 31/33 20060101ALI20251127BHEP

Ipc: A61K 31/395 20060101ALI20251127BHEP

Ipc: A61K 31/4725 20060101ALI20251127BHEP

Ipc: A61P 35/00 20060101ALI20251127BHEP